ABI
TEVA icon

Adamant Biomedical Investments’s Teva Pharmaceuticals TEVA Stock Holding History

Adamant Biomedical Investments’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		$2.88M Sell
50,000
-70,000
-58% -$3.9M 0.69% 51
2014
Q3 		$6.45M Buy
+120,000
New +$6.36M 1.61% 20

Other funds holding TEVA

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Adamant Biomedical Investments's TEVA Position: Q4 2014 in Review

Adamant Biomedical Investments reduced its Teva Pharmaceuticals (TEVA) stake by 58% in Q4 2014, selling an estimated $3.9M and leaving 50,000 shares worth $2.88M. The position accounts for 0.69% of the portfolio, ranked #51.

Adamant Biomedical Investments first reported a position in TEVA in Q3 2014 and has held it in 2 quarters since. The position peaked at $6.45M in Q3 2014. 821 funds tracked by Wall St. Rank hold TEVA as of Q4 2014.

  • Adamant Biomedical Investments held 50,000 shares of Teva Pharmaceuticals worth $2.88M as of Q4 2014.
  • Adamant Biomedical Investments sold 70,000 Teva Pharmaceuticals shares in Q4 2014, an estimated $3.9M.
  • Teva Pharmaceuticals made up 0.69% of Adamant Biomedical Investments's portfolio in Q4 2014, its #51 holding.
  • Adamant Biomedical Investments first reported a position in Teva Pharmaceuticals in Q3 2014 and has held it in 2 quarters since.
  • Adamant Biomedical Investments's Teva Pharmaceuticals position peaked at $6.45M in Q3 2014.
  • 821 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2014.

Based on Adamant Biomedical Investments's 13F filing for Q4 2014, filed 13 Feb 2015.